blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2344161

EP2344161 - COMBINATIONS OF A LIPOSOMAL WATER-SOLUBLE CAMPTOTHECIN WITH CETUXIMAB OR BEVACIZUMAB [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.10.2019
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  16.11.2018
FormerGrant of patent is intended
Status updated on  30.07.2018
FormerExamination is in progress
Status updated on  10.08.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Celator Pharmaceuticals, Inc.
200 Princeton South Corporate Center, Suite 180
Ewing, NJ 08628 / US
[2016/51]
Former [2011/29]For all designated states
Celator Pharmaceuticals Corporation
1779 West 75th Avenue
Vancouver, British Columbia V6P 6P2 / CA
Inventor(s)01 / TARDI, Paul
16348 60th Avenue
Surrey, British Columbia V3S 1S4 / CA
02 / MAYER, Lawrence
2416 Carmaria Court
North Vancouver British Columbia V7J 3M4 / CA
03 / BERMUDES, David
2081 Adobe Canyon Road
Kenwood CA 95452 / US
 [2018/51]
Former [2011/29]01 / TARDI, Paul
19081 Sundale Court
Surrey British Columbia V3S 7M6 / CA
02 / MAYER, Lawrence
2416 Carmaria Court
North Vancouver British Columbia V7J 3M4 / CA
03 / BERMUDES, David
2081 Adobe Canyon Road
Kenwood CA 95452 / US
Representative(s)V.O.
P.O. Box 87930
2508 DH Den Haag / NL
[2018/51]
Former [2011/29]Jansen, Cornelis Marinus, et al
VEREENIGDE Johan de Wittlaan 7
2517 JR Den Haag / NL
Application number, filing date09820164.316.10.2009
[2011/29]
WO2009CA01483
Priority number, dateUS20080106109P16.10.2008         Original published format: US 106109 P
[2011/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010043050
Date:22.04.2010
Language:EN
[2010/16]
Type: A1 Application with search report 
No.:EP2344161
Date:20.07.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 22.04.2010 takes the place of the publication of the European patent application.
[2011/29]
Type: B1 Patent specification 
No.:EP2344161
Date:19.12.2018
Language:EN
[2018/51]
Search report(s)International search report - published on:CA22.04.2010
(Supplementary) European search report - dispatched on:EP12.06.2014
ClassificationIPC:A61K31/4745, A61K31/496, A61K31/513, A61K31/7072, A61K39/395, A61K9/127, A61P35/00
[2011/29]
CPC:
A61K9/127 (EP,US); A61K31/4745 (EP,US); A61K31/496 (EP,US);
A61K31/513 (EP,US); A61K31/7072 (EP,US); A61K39/39558 (EP,US);
A61P35/00 (EP) (-)
C-Set:
A61K31/4745, A61K2300/00 (EP,US);
A61K31/496, A61K2300/00 (US,EP);
A61K31/513, A61K2300/00 (US,EP);
A61K31/7072, A61K2300/00 (US,EP);
A61K39/39558, A61K2300/00 (EP,US)
(-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2018/51]
Former [2011/29]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:KOMBINATIONEN EINES LIPOSOMALEN WASSERLÖSLICHEN CAMPTOTHECINS MIT CETUXIMAB ODER BEVACIZUMAB[2011/29]
English:COMBINATIONS OF A LIPOSOMAL WATER-SOLUBLE CAMPTOTHECIN WITH CETUXIMAB OR BEVACIZUMAB[2011/29]
French:COMBINAISONS D'UNE CAMPTOTHÉCINE DE LIPOSOME SOLUBLE DANS L'EAU AVEC DU CETUXIMAB OU DU BEVACIZUMAB[2011/29]
Entry into regional phase11.05.2011National basic fee paid 
11.05.2011Search fee paid 
11.05.2011Designation fee(s) paid 
11.05.2011Examination fee paid 
Examination procedure11.05.2011Examination requested  [2011/29]
19.12.2014Amendment by applicant (claims and/or description)
06.04.2016Despatch of a communication from the examining division (Time limit: M06)
22.08.2016Reply to a communication from the examining division
31.07.2017Despatch of a communication from the examining division (Time limit: M04)
27.10.2017Reply to a communication from the examining division
08.05.2018Despatch of a communication from the examining division (Time limit: M04)
18.06.2018Reply to a communication from the examining division
31.07.2018Communication of intention to grant the patent
05.11.2018Fee for grant paid
05.11.2018Fee for publishing/printing paid
05.11.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  06.04.2016
Opposition(s)20.09.2019No opposition filed within time limit [2019/48]
Fees paidRenewal fee
11.10.2011Renewal fee patent year 03
11.10.2012Renewal fee patent year 04
14.10.2013Renewal fee patent year 05
14.10.2014Renewal fee patent year 06
12.10.2015Renewal fee patent year 07
11.10.2016Renewal fee patent year 08
11.10.2017Renewal fee patent year 09
11.10.2018Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.10.2009
AT19.12.2018
CY19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
MK19.12.2018
MT19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
TR19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
[2022/31]
Former [2021/34]HU16.10.2009
AT19.12.2018
CY19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
MT19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
TR19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2021/32]HU16.10.2009
AT19.12.2018
CY19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
TR19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2021/26]AT19.12.2018
CY19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
TR19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2020/29]AT19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
TR19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2020/17]AT19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
TR19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2020/13]AT19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2019/48]AT19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
SE19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2019/46]AT19.12.2018
CZ19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
SE19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2019/39]CZ19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
SE19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2019/37]CZ19.12.2018
EE19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
SE19.12.2018
SM19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
PT19.04.2019
Former [2019/35]CZ19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
SE19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
PT19.04.2019
Former [2019/33]FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
SE19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
PT19.04.2019
Former [2019/30]FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
SE19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
Former [2019/25]FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
SE19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
Former [2019/23]FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
BG19.03.2019
NO19.03.2019
Former [2019/22]FI19.12.2018
LT19.12.2018
BG19.03.2019
NO19.03.2019
Former [2019/21]FI19.12.2018
LT19.12.2018
NO19.03.2019
Former [2019/20]LT19.12.2018
NO19.03.2019
Documents cited:Search[YD]WO2004087115  (CELATOR TECHNOLOGIES INC [CA], et al) [YD] 1-15 * the whole document *;
 [Y]  - S. SATHORNSUMETEE ET AL, "Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan", JOURNAL OF CLINICAL ONCOLOGY, (20080110), vol. 26, no. 2, doi:10.1200/JCO.2007.13.3652, ISSN 0732-183X, pages 271 - 278, XP055121262 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1200/JCO.2007.13.3652
International search[Y]WO03030864  (NEOPHARM INC [US], et al);
 [Y]WO2004087115  (CELATOR TECHNOLOGIES INC [CA], et al);
 [Y]WO2005002546  (SMITHKLINE BEECHAM CORP [US], et al);
 [Y]WO2005117877  (HOFFMANN LA ROCHE [CH], et al);
 [YP]WO2009024667  (AVENTIS PHARMA SA [FR], et al);
 [Y]  - KIM ET AL., "Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice", CLIN. CANCER RES., (2006), vol. 12, no. 2, pages 600 - 607, XP008136963

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-05-1325
 [Y]  - MAHTANI ET AL., "Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract", ONCOLOGIST, (2008), vol. 13, pages 39 - 50, XP008137142

DOI:   http://dx.doi.org/10.1634/theoncologist.2006-0049
Examination   - OOYAMA A ET AL, "Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts", CANCER LETTERS, NEW YORK, NY, US, vol. 267, no. 1, doi:10.1016/J.CANLET.2008.03.008, ISSN 0304-3835, (20080818), pages 26 - 36, (20080416), XP022797039

DOI:   http://dx.doi.org/10.1016/j.canlet.2008.03.008
by applicantEP0520722
 EP0564409
 EP0566226
 WO9410202
 WO9503283
 WO9630347
 WO9633980
 WO9702266
 EP0769947
 EP0787722
 WO9730034
 WO9738983
 WO9749688
 WO9811223
 WO9810767
 EP0837063
 US5747498
 WO9835958
 WO9903854
 WO0009495
 WO0027820
 WO0027819
 WO0037502
 WO0059509
 WO0062235
 WO0066125
 US6403569
 WO03028696
 WO2004087115
    - FREI et al., Clin. Cancer Res., (19980000), vol. 4, pages 2027 - 2037
    - FISHER, M. D., Clin Colorectal Cancer, (20010800), vol. l, no. 2, pages 85 - 86
    - FURUTA, T. et al., Gan To Kagaku Ryoho, (19910300), vol. 18, no. 3, pages 393 - 402
    - KIM et al., Clin. Cancer Res., (20060000), vol. 12, no. 2, pages 600 - 607
    - PREWETT, M. et al., Cancer Research, (19990000), vol. 59, pages 5209 - 5218
    - YUAN, F. et al., Proc. Natl. Acad. Sci. USA, (19960000), vol. 93, pages 14765 - 14770
    - ZHU, Z. et al., Cancer Res., (19980000), vol. 58, pages 3209 - 3214
    - MORDENTI, J. et al., Toxicologic Pathology, (19990000), vol. 27, pages 14 - 21
    - O'REILLY, M. S. et al., Cell, (19940000), vol. 79, pages 315 - 328
    - O'REILLY, M. S. et al., Cell, (19970000), vol. 88, pages 277 - 285
    - A.S. Janoff,, Liposomes: Rational Design, Marcel Dekker, Inc.
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.